US 12,187,749 B2
Application of dipyrrinato-iridium complexes in anti-tumor and anti-bacterial therapy
Benjamin Florian Hohlfeld, Berlin (DE); Arno Wiehe, Berlin (DE); Burkhard Gitter, Jena (DE); Dorika Steen, Jena (DE); Gerhard Wieland, Jena (DE); and Volker Albrecht, Nuthetal (DE)
Assigned to BIOLITEC UNTERNEHMENSBETEILIGUNGS III AG, Vienna (AT)
Filed by BIOLITEC UNTERGEHMENSBETEILIGUNGS II AG, Vienna (AT)
Filed on Jan. 31, 2023, as Appl. No. 18/162,205.
Application 18/162,205 is a continuation of application No. PCT/EP2021/071590, filed on Aug. 2, 2021.
Claims priority of provisional application 63/060,572, filed on Aug. 3, 2020.
Prior Publication US 2023/0242559 A1, Aug. 3, 2023
Int. Cl. C07F 15/00 (2006.01); A61K 41/00 (2020.01); A61K 47/54 (2017.01); A61P 31/04 (2006.01); A61P 35/00 (2006.01); C07F 17/02 (2006.01)
CPC C07F 15/0033 (2013.01) [A61K 41/0057 (2013.01); A61K 47/549 (2017.08); A61P 31/04 (2018.01); A61P 35/00 (2018.01); C07F 17/02 (2013.01)] 12 Claims
 
1. An iridium compound of formula 1, 2, 3 or 4:

OG Complex Work Unit Chemistry
Wherein:
X is at least one of O, NH or S;
R1 is at least one of a carbohydrate moiety, a short alkyl chain with 3 to 6 carbon atoms, propargyl, HO—CH2—CH2—, CH(CH2OH)2, CH2—CH(OH)—CH2OH, or CH(OH)—CH(OH)—CH3; and
R2 is at least one of hydrogen or a methyl group.